Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Dec 26, 2024; 16(12): 1062-1085
Published online Dec 26, 2024. doi: 10.4252/wjsc.v16.i12.1062
Published online Dec 26, 2024. doi: 10.4252/wjsc.v16.i12.1062
Mesenchymal stem cell therapy in atherosclerosis: A bibliometric and visual analysis
Xing Cheng, Ya-Ling Li, Heng Wang, Ke-Yi Fan, Xiao-Tong Qi, Guo-Ping Zheng, Hong-Lin Dong, Department of Vascular Surgery, The Second Hospital of Shanxi Medical University, Taiyuan 030000, Shanxi Province, China
Heng Wang, Guo-Ping Zheng, Centre for Transplant and Renal Research, Westmead Institute for Medical Research, The University of Sydney, Sydney 2145, New South Wales, Australia
Rui-Jing Zhang, Department of Nephrology, The Second Hospital of Shanxi Medical Uni
Co-first authors: Xing Cheng and Ya-Ling Li.
Co-corresponding authors: Guo-Ping Zheng and Hong-Lin Dong.
Author contributions: Cheng X, Li YL, and Wang H contributed equally to this study. Zheng GP and Dong HL designed the research study; Zheng GP and Dong HL are the co-corresponding authors of this manuscript; Cheng X, Li YL, and Wang H conducted the data analysis, interpretation, figures and tables drawing, and manuscript writing; Zhang RJ conducted the data collection; Fan KY and Qi XT conducted the assembly of data and drawing of figures and tables; and all authors have read and approved the final manuscript.
Supported by the Regional Cooperation Program of Shanxi Province, China, No. 202204041101038; the Construction and Demonstration of the Molecular Diagnosis and Treatment Platform for Vascular Diseases in Shanxi Province, China, No. SCP-2023-17; and Translational Medicine Engineering Research Center for Vascular Diseases of Shanxi Province, China, No. 2022017.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong-Lin Dong, MD, Department of Vascular Surgery, The Second Hospital of Shanxi Medical University, No. 382 Wuyi Road, Xinghualing District, Taiyuan 030000, Shanxi Province, China. honglindong@sxmu.edu.cn
Received: May 3, 2024
Revised: October 15, 2024
Accepted: November 18, 2024
Published online: December 26, 2024
Processing time: 223 Days and 20.6 Hours
Revised: October 15, 2024
Accepted: November 18, 2024
Published online: December 26, 2024
Processing time: 223 Days and 20.6 Hours
Core Tip
Core Tip: This study provided a comprehensive overview of the research landscape on mesenchymal stem cell therapy in atherosclerosis through detailed bibliometric analysis. It not only collated and presented key studies in this field but also highlighted emerging trends, significant developments, and potential future research directions, providing a valuable foundation for further exploration and application of stem cell therapy in the treatment of atherosclerosis.